A two-year follow-up study of cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells in ischemic stroke patients.

Stem cell therapy is an emerging therapeutic modality in the treatment of stroke. We assessed the safety and feasibility of the cotransplantation of neural stem/progenitor cells (NSPCs) and mesenchymal stromal cells (MSCs) in patients with ischemic stroke. Eight patients were enrolled in this study.

[Effects of altered peptide ligands (APLs) of proteolipid(136-150) on T-cell clone 4B.14a].

Aim: By investigating the effects of APLs of PLP(136-150) on T cell clone 4B.14a in-vitro and in-vivo, to determine the feasibility of APLs to prevent relapsing multiple sclerosis (MS) in human.

Methods: To mimic the clinic course of relapsing MS, SJL/J female mice were first irradiated at 450R and intravenously infused with 1x10(7) resting 4B.